- Home
- DHR vs SNY Comparison
DHR vs SNY Comparison
Compare DHR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | SNY |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.6B | 110.4B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | DHR | SNY |
|---|---|---|
| Price | $167.36 | $42.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $241.69 | $58.00 |
| AVG Volume (30 Days) | ★ 4.8M | 2.5M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | 0.89% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $19,893,000,000.00 | N/A |
| Revenue This Year | $5.43 | $3.49 |
| Revenue Next Year | $5.74 | $6.10 |
| P/E Ratio | $118.10 | ★ $6.14 |
| Revenue Growth | ★ 8.53 | N/A |
| 52 Week Low | $170.74 | $42.78 |
| 52 Week High | $242.80 | $53.36 |
Technical Indicators
Market Signals| Indicator | DHR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 26.39 | 30.37 |
| Support Level | N/A | N/A |
| Resistance Level | $198.50 | $48.76 |
| Average True Range (ATR) | 4.94 | 0.73 |
| MACD | -0.89 | -0.43 |
| Stochastic Oscillator | 8.50 | 2.97 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.